ES2056173T3 - Analisis de lipoproteina en sangre por resonancia magnetica nuclear. - Google Patents

Analisis de lipoproteina en sangre por resonancia magnetica nuclear.

Info

Publication number
ES2056173T3
ES2056173T3 ES89116979T ES89116979T ES2056173T3 ES 2056173 T3 ES2056173 T3 ES 2056173T3 ES 89116979 T ES89116979 T ES 89116979T ES 89116979 T ES89116979 T ES 89116979T ES 2056173 T3 ES2056173 T3 ES 2056173T3
Authority
ES
Spain
Prior art keywords
magnetic resonance
nuclear magnetic
blood lipoprotein
lipoprotein analysis
analysis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89116979T
Other languages
English (en)
Inventor
James D Otvos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of ES2056173T3 publication Critical patent/ES2056173T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00—Arrangements or instruments for measuring magnetic variables
    • G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
    • G01R33/46—NMR spectroscopy
    • G01R33/465—NMR spectroscopy applied to biological material, e.g. in vitro testing
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S128/00—Surgery
    • Y10S128/92—Computer assisted medical diagnostics
    • Y10S128/922—Computer assisted medical diagnostics including image analysis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/24—Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry

Landscapes

  • Physics & Mathematics (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • General Physics & Mathematics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)

Abstract

METODO Y APARATO PARA DETERMINAR, EN UN ANALISIS DE PLASMA SANGUINEO, LA CONCENTRACION DE LOS COMPONENETES DE LIPOPROTEINA, VLDL, LDL, HDL Y PROTEINAS INCLUIDAS, OBTENIDA POR EL MOVIMIENTO DEL ESPECTRO QUIMICO DEL NMR DE UNA MUESTRA. TOMANDO COMO REFERENCIA EL ESPECTRO NMR DE LA LIPOPROTEINA Y LOS COMPONENTES SE JUNTAN PARA FORMAR UNA LINEA DE DESARROLLO QUE MIDA EL REGISTRO SUPERIOR DEL ESPECTRO NMR DEL PLASMA SANGUINEO, Y DESPUES DE ESTO QUEDA DETERMINADA LA CONCENTRACION DE CADA LIPOPROTEINA Y CONSTITUYENTES EN EL PLASMA SANGUINEO.
ES89116979T 1988-09-26 1989-09-13 Analisis de lipoproteina en sangre por resonancia magnetica nuclear. Expired - Lifetime ES2056173T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/248,750 US4933844A (en) 1988-09-26 1988-09-26 Measurement of blood lipoprotein constituents by analysis of data acquired from an NMR spectrometer

Publications (1)

Publication Number Publication Date
ES2056173T3 true ES2056173T3 (es) 1994-10-01

Family

ID=22940515

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89116979T Expired - Lifetime ES2056173T3 (es) 1988-09-26 1989-09-13 Analisis de lipoproteina en sangre por resonancia magnetica nuclear.

Country Status (6)

Country Link
US (1) US4933844A (es)
EP (1) EP0361214B1 (es)
JP (1) JP3059181B2 (es)
CA (1) CA1327993C (es)
DE (1) DE68916729T2 (es)
ES (1) ES2056173T3 (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5192264A (en) * 1989-10-06 1993-03-09 The Beth Israel Hospital Association Methods and apparatus for treating disease states using oxidized lipoproteins
US5366440A (en) * 1989-10-06 1994-11-22 The Beth Israel Hospital Association Methods for treating disease states using oxidized lipoproteins in conjunction with chemotherapeutic effector agents
EP0494969A4 (en) * 1989-10-06 1992-09-16 The Beth Israel Hospital Association Nmr apparatus and method for detecting cancer
WO1991010128A1 (en) * 1989-12-21 1991-07-11 The Beth Israel Hospital Association Method for predicting atherosclerotic risk
SE9001698L (sv) * 1990-05-10 1991-11-11 Chiscan Ab En metod foer att upptaecka maligniteter
US5207715A (en) * 1990-07-24 1993-05-04 The Beth Israel Hospital Association Method of detecting cancer by measuring lipid-peroxidation using NMR
WO1993003450A1 (en) * 1991-07-30 1993-02-18 North Carolina State University Method and apparatus for measuring blood lipoprotein levels by nmr spectroscopy
WO1993021517A1 (en) * 1992-04-10 1993-10-28 The Beth Israel Hospital Association Measurement of propensity to atherosclerosis; oxidizability of olefinic residues of plasma lipoproteins and lipids
JPH08501633A (ja) * 1992-09-24 1996-02-20 パーセプティブ バイオシステムズ インコーポレイテッド Ｌｄｌの定量
US6104191A (en) * 1998-03-17 2000-08-15 General Electric Company Quantitative in vivo spectroscopy using oversampling, waterline referencing, and prior knowledge fitting
WO2000051054A1 (en) 1999-02-26 2000-08-31 Lipomed, Inc. Methods, systems, and computer program products for analyzing and presenting risk assessment results based on nmr lipoprotein analysis of blood
US6653140B2 (en) 1999-02-26 2003-11-25 Liposcience, Inc. Methods for providing personalized lipoprotein-based risk assessments
EP1171778B1 (en) 1999-04-22 2006-03-01 Liposcience, Inc. Nmr-method for determining the risk of developing type 2 diabetes
GB2410559B (en) * 2001-01-15 2005-09-28 Chenomx Inc Process, apparatus, media and signals for automatically identifying compounds in a sample
CA2331116A1 (en) * 2001-01-15 2002-07-15 Chenomx, Inc. Compound identification and quantitation in liquid mixtures -- method and process using an automated nuclear magnetic resonance measurement system
US20030028093A1 (en) * 2001-04-20 2003-02-06 Yong Ke Exponential decay modeling in spectroscopy
WO2003012416A1 (en) * 2001-08-01 2003-02-13 Liposcience, Inc. Method of determining presence and concentration of lipoprotein x in blood plasma and serum
CA2467420A1 (en) * 2001-11-13 2003-05-22 The Regents Of The University Of California Ion mobility analysis of biological particles
WO2004040407A2 (en) * 2002-10-25 2004-05-13 Liposcience, Inc. Methods, systems and computer programs for deconvolving the spectral contribution of chemical constituents with overlapping signals
CA2542107A1 (en) * 2003-10-23 2005-05-12 Liposcience, Inc. Methods, systems and computer programs for assessing chd risk using mathematical models that consider in vivo concentration gradients of ldl particle subclasses of discrete size
WO2005098463A2 (en) * 2004-04-01 2005-10-20 Liposcience, Inc. Nmr clinical analyzers and related methods, systems, modules and computer program products for clinical evaluation of biosamples
US7064544B1 (en) * 2004-05-18 2006-06-20 General Electric Company Method and system of scaling MR spectroscopic data acquired with phased-array coils
DE102004026903B4 (de) * 2004-06-01 2006-05-18 Universität Regensburg Verfahren zur Bestimmung von Lipoproteinen in Körperflüssigkeiten und Messanordnung dafür
US20070207516A1 (en) * 2005-12-21 2007-09-06 Doupe Thomas H Cholesterol measurement system and method
WO2007133593A2 (en) * 2006-05-10 2007-11-22 Liposcience, Inc. Methods, systems and computer programs for assessing chd risk using weighted hdl particle number measurements
US8247235B2 (en) 2007-06-08 2012-08-21 Quest Diagnostics Investments Incorporated Lipoprotein analysis by differential charged-particle mobility
US20080302666A1 (en) * 2007-06-08 2008-12-11 Benner W Henry Apparatus for differential charged-particle mobility
US9354200B1 (en) 2008-08-07 2016-05-31 Quest Diagnostics Investments Incorporated Detection apparatus for differential-charged particle mobility analyzer
KR20110086074A (ko) * 2008-10-20 2011-07-27 리포사이언스, 인크. 지질단백질 인슐린 저항성 지표 및 이와 관련된 방법, 시스템 및 이를 생성하기 위한 컴퓨터 프로그램
DE102009026651A1 (de) 2009-06-02 2011-02-17 Großmann, Kay, Dr. rer. nat. (Chemie) Verfahren und Messvorrichtung zur qualitativen und quantitativen Analyse von Körperflüssigkeiten
EP2270530B1 (en) * 2009-07-01 2013-05-01 Københavns Universitet Method for prediction of lipoprotein content from NMR data
KR20140040290A (ko) 2009-07-22 2014-04-02 일라이 릴리 앤드 캄파니 제약 요법과 관련된 체중 증가를 예측하기 위한 방법
US9250211B2 (en) 2010-12-30 2016-02-02 Quest Diagnostics Investments Incorporated Magnetic separation of lipoproteins using dextran sulfate
US9483612B2 (en) 2012-04-27 2016-11-01 Liposcience, Inc. CHD risk stratification evaluations for subjects with high levels of large HDL-P
US9928345B2 (en) 2012-06-08 2018-03-27 Liposciences, Inc. Multiple-marker risk parameters predictive of conversion to diabetes
US9361429B2 (en) 2012-06-08 2016-06-07 Liposcience, Inc. Multi-parameter diabetes risk evaluations
US9470771B2 (en) 2012-06-08 2016-10-18 Liposcience, Inc. NMR measurements of NMR biomarker GlycA
WO2014059025A1 (en) 2012-10-09 2014-04-17 Liposcience, Inc. Nmr quantification of branched chain amino acids
US20150260631A1 (en) * 2014-03-17 2015-09-17 Health Diagnostic Laboratory, Inc. System and method for assessing quanitites or sizes of lipoprotein particles from lipoprotein particle compositions
US9551768B2 (en) 2013-03-15 2017-01-24 East Carolina University NMR method for monitoring changes in the core of lipoprotein particles in metabolism and disease
EP3021874B1 (en) * 2013-07-18 2022-04-27 The University of Hong Kong Methods for classifying pleural fluid
PT3074775T (pt) * 2013-11-27 2018-10-31 Inst Dinvestigacio Sanitaria Pere Virgili Método para a caracterização de lipoproteínas
US9952232B2 (en) 2014-09-11 2018-04-24 Liposcience, Inc. Cardiovascular risk evaluations using a risk parameter that includes an HDL and inflammatory biomarker interaction parameter
EP3258285B1 (en) * 2016-06-14 2020-10-21 Bruker BioSpin GmbH Method for predicting chemical shift values of nmr spin systems in a sample of a fluid class, in particular in a sample of a biofluid
DE102016224691A1 (de) * 2016-12-12 2018-06-14 Numares Ag Verfahren zur Analyse eines NMR-Spektrums einer lipoproteinhaltigen Probe
CA3073827C (en) 2017-09-07 2023-10-17 Liposcience, Inc. Multi-parameter metabolic vulnerability index evaluations
US11467171B2 (en) 2017-11-10 2022-10-11 Liposcience, Inc. Methods and systems to detect and quantify the amount of LP-X and other abnormal lipoproteins in a biosample using NMR spectroscopy
CN113614540B (zh) * 2018-11-08 2025-05-02 力保科学公司 使用脂蛋白lp-z预测肝病死亡率的方法
DE102023110285B3 (de) 2023-04-21 2024-05-08 Universität zu Lübeck, Körperschaft des öffentlichen Rechts Nmr-messung von glykoproteinen

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US28803A (en) * 1860-06-19 Coffee-pot
USRE28803E (en) 1971-09-09 1976-05-04 American Monitor Corporation Method and electronic control for the analyzation of serum chemistries
US3950135A (en) * 1974-07-24 1976-04-13 Massachusetts Institute Of Technology Method of sepctral analysis using nmr shift reagents
US4224031A (en) * 1977-11-15 1980-09-23 Mee John M L CI Mass spectrometric analysis of physiologically active compounds
US4720788A (en) * 1984-06-20 1988-01-19 Helena Laboratories Corporation Diagnostic densitometer
GB8520587D0 (en) * 1985-08-16 1985-09-25 Picker Int Ltd Spectroscopy method
IL81276A (en) * 1986-02-26 1991-05-12 Beth Israel Hospital Process for the screening of cancer using nuclear magnetic resonance spectroscopy
DE3617161A1 (de) * 1986-05-22 1987-11-26 Boehringer Mannheim Gmbh System zur bestimmung der konzentration von bestandteilen von koerperfluessigkeiten

Also Published As

Publication number Publication date
DE68916729D1 (de) 1994-08-18
JPH02116743A (ja) 1990-05-01
EP0361214B1 (en) 1994-07-13
CA1327993C (en) 1994-03-22
DE68916729T2 (de) 1994-12-08
EP0361214A1 (en) 1990-04-04
US4933844A (en) 1990-06-12
JP3059181B2 (ja) 2000-07-04

Similar Documents

Publication Publication Date Title
ES2056173T3 (es) Analisis de lipoproteina en sangre por resonancia magnetica nuclear.
BR9007206A (pt) Processo para medir,pelo menos,um constituinte de uma amostra fluida,por meio de um dispositivo de eletrodo,aparelhagem de medida para uso no processo,eletrodo sensivel e aparelhagem para conducao do processo
ES2086230T3 (es) Metodo para mejorar la precision de las mediciones en ensayos con biosensores opticos de ondas evanescentes.
ES2112057T3 (es) Metodo de deteccion y/o cuantificacion y/o separacion de celulas apoptosicas dentro de o en una muestra.
SE7906148L (sv) Forfarande for framstellning av en biologisk komposition for anvendning sasom referenskontroll vid diagnostiska tester
SE8701054D0 (sv) Magnetic resonance analysis of substances in samples that include dissipative material
ES2050683T3 (es) Analizador optico de gas.
ES556820A0 (es) Un conjunto de bandeja de especimenes para uso en un sistema automatizado de analisis, para analizar dichos especimenes
BR8302286A (pt) Aperfeicoamento em processo para determinacao da presenca de um analisador em uma amostra, aparelho de diagnostico inteiramente calibrado e kit para uso em um ensaio diagnostico
ES2035561T3 (es) Analizador volumetrico de sangre multipunto, automatizado.
ES2152578T3 (es) Indices identificadores para bases de datos.
ES2115584T3 (es) Antigeno sintetico para la deteccion de enfermedades referentes al sida.
ATE108904T1 (de) Verfahren zur untersuchung von relaxationsspektren und resonanzen in materialien.
ES2038594T3 (es) Analisis de fluidos por medio del uso de una fuente de neutrones rapidos.
ATE294962T1 (de) Industrielle online-analyse mittels kernspinresonanzspektroskopie
DK241580A (da) Fremgangsmaade og apparat til cirkulering ved pumpning af en organisk-biologisk vaeske isaer blod
DK509686A (da) Fremgangsmaade og apparat til bestemmelse af antistofindholdet i blod
IT7968578A0 (it) Dispositivo e procedimento per la determinazione della concentrazione di un costituente in un campione per via cromatografica e ottica
SE8800767L (sv) Nmr-apparat foer undersoekning av en kropp, saerskilt foer avbildning av maenniskokroppens hud, och anordning foer alstring av en magnetfaeltsgradient i en saadan apparat
Nanthasurasak et al. In‐Transit Electroextraction of Small‐Molecule Pharmaceuticals from Blood
SE7706471L (sv) Forfarande och anordning for magnetisk provning av material
ES8604693A1 (es) Un metodo para detectar un anticuerpo o un antigeno contenido en una muestra de fluido de origen biologico.
ATE67315T1 (de) Verfahren zur durchfuehrung von immunfluoreszenztesten.
ES2175123T3 (es) Procedimiento que sirve para determinar la concentracion de oxigeno enuna muestra.
ES2080955T3 (es) Anticuerpos especificos de la pancreaelastasa 1, procedimiento para su obtencion y equipo de analisis que contiene este tipo de anticuerpos.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 361214

Country of ref document: ES